RU2019113752A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019113752A3 RU2019113752A3 RU2019113752A RU2019113752A RU2019113752A3 RU 2019113752 A3 RU2019113752 A3 RU 2019113752A3 RU 2019113752 A RU2019113752 A RU 2019113752A RU 2019113752 A RU2019113752 A RU 2019113752A RU 2019113752 A3 RU2019113752 A3 RU 2019113752A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407186P | 2016-10-12 | 2016-10-12 | |
| US62/407,186 | 2016-10-12 | ||
| PCT/US2017/056147 WO2018071548A1 (en) | 2016-10-12 | 2017-10-11 | Apilimod compositions and methods for using same in the treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019113752A RU2019113752A (ru) | 2020-11-13 |
| RU2019113752A3 true RU2019113752A3 (enExample) | 2021-01-19 |
Family
ID=60268450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019113752A RU2019113752A (ru) | 2016-10-12 | 2017-10-11 | Композиции апилимода и способы их применения при лечении болезни альцгеймера |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190365771A1 (enExample) |
| EP (1) | EP3525794A1 (enExample) |
| JP (1) | JP7199349B2 (enExample) |
| KR (1) | KR20190067824A (enExample) |
| CN (1) | CN110167559A (enExample) |
| AU (1) | AU2017342262B2 (enExample) |
| BR (1) | BR112019007214A2 (enExample) |
| CA (1) | CA3039199A1 (enExample) |
| IL (1) | IL265911A (enExample) |
| MX (1) | MX2019004179A (enExample) |
| RU (1) | RU2019113752A (enExample) |
| WO (1) | WO2018071548A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019223014B2 (en) * | 2018-02-21 | 2024-10-17 | Orphai Therapeutics Inc. | Combination therapy with apilimod and glutamatergic agents |
| US12589097B2 (en) | 2018-02-21 | 2026-03-31 | OrphAl Therapeutics Inc. | Apilimod compositions and methods of use |
| CN116059192B (zh) | 2019-11-13 | 2024-10-29 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| CA3167339A1 (en) | 2020-01-13 | 2021-07-22 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006053112A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Process for preparing trisubstituted pyrimidine compounds |
| US7863270B2 (en) | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| EP2661445A2 (en) | 2011-01-04 | 2013-11-13 | Universität Zürich | Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease |
| PT3215157T (pt) * | 2014-11-07 | 2019-07-12 | Ai Therapeutics Inc | Apilimod para utilização no tratamento de melanoma |
| US10206910B2 (en) * | 2014-11-07 | 2019-02-19 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
| WO2016118709A1 (en) * | 2015-01-23 | 2016-07-28 | Lam Therapeutics, Inc. | Anti-viral compositions containing pikfyve inhibitors and use thereof |
| EP3253389A4 (en) * | 2015-02-03 | 2018-07-18 | LAM Therapeutics, Inc. | Apilimod compositions and methods for using same |
| US10758545B2 (en) * | 2015-06-25 | 2020-09-01 | University Of Southern California | Methods to treat neurological diseases |
-
2017
- 2017-10-11 RU RU2019113752A patent/RU2019113752A/ru not_active Application Discontinuation
- 2017-10-11 JP JP2019519652A patent/JP7199349B2/ja active Active
- 2017-10-11 KR KR1020197012287A patent/KR20190067824A/ko not_active Ceased
- 2017-10-11 US US16/340,845 patent/US20190365771A1/en not_active Abandoned
- 2017-10-11 BR BR112019007214A patent/BR112019007214A2/pt not_active Application Discontinuation
- 2017-10-11 WO PCT/US2017/056147 patent/WO2018071548A1/en not_active Ceased
- 2017-10-11 AU AU2017342262A patent/AU2017342262B2/en not_active Ceased
- 2017-10-11 CN CN201780076520.2A patent/CN110167559A/zh active Pending
- 2017-10-11 MX MX2019004179A patent/MX2019004179A/es unknown
- 2017-10-11 EP EP17794818.9A patent/EP3525794A1/en not_active Withdrawn
- 2017-10-11 CA CA3039199A patent/CA3039199A1/en active Pending
-
2019
- 2019-04-08 IL IL265911A patent/IL265911A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL265911A (en) | 2019-06-30 |
| US20190365771A1 (en) | 2019-12-05 |
| MX2019004179A (es) | 2019-09-02 |
| AU2017342262B2 (en) | 2023-09-28 |
| CN110167559A (zh) | 2019-08-23 |
| AU2017342262A1 (en) | 2019-04-18 |
| CA3039199A1 (en) | 2018-04-19 |
| BR112019007214A2 (pt) | 2019-07-02 |
| KR20190067824A (ko) | 2019-06-17 |
| WO2018071548A1 (en) | 2018-04-19 |
| EP3525794A1 (en) | 2019-08-21 |
| RU2019113752A (ru) | 2020-11-13 |
| JP7199349B2 (ja) | 2023-01-05 |
| JP2019530711A (ja) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018068177A2 (enExample) | ||
| BR112019002665A2 (enExample) | ||
| BR112018004986A2 (enExample) | ||
| BR112019001429A2 (enExample) | ||
| BR212018070320U2 (enExample) | ||
| BR112019009203A2 (enExample) | ||
| BR112019011044B1 (pt) | Compostos de pirazol substituído, seu uso, e composição farmacêutica | |
| BR112019008501B1 (pt) | Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador | |
| BR112019003116B1 (pt) | Configuração de símbolo de rajada comum de uplink | |
| BR112019001236B1 (pt) | Método para executar uma função suplementar para uma consulta de linguagem natural apresentada a um aplicativo de orientação de mídia interativa | |
| BR112018076493B1 (pt) | Sistemas e métodos para detecção de posição de feixe de luz | |
| BR112018073794B1 (pt) | Partícula, método de geração da partícula, vacina ou composição farmacêutica | |
| BR122026002520A2 (pt) | Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno | |
| BR212019008871U2 (enExample) | ||
| BR112019006736A2 (enExample) | ||
| BR102016018018A2 (enExample) | ||
| BE2016C016I2 (enExample) | ||
| CN303648624S (enExample) | ||
| CN303536128S (enExample) | ||
| CN303536593S (enExample) | ||
| CN303536240S (enExample) | ||
| CN303611042S (enExample) | ||
| CN303536207S (enExample) | ||
| CN303606547S (enExample) | ||
| CN303536497S (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20220114 |